Regulatory Story
Go to market news section View chart   Print
Octopus AIM VCT 2 plc   -  OSEC   

Half-year report

Released 12:15 24-Jul-2019

Half-year report

Half-yearly Results

24 July 2019

Octopus AIM VCT 2 plc, managed by Octopus Investments Limited, today announces the half-yearly results for the six months ended 31 May 2019.

These results were approved by the Board of Directors on 24 July 2019.

You may shortly view the half-yearly report in full by visiting https://www.octopusinvestments.com/investor/our-products/venture-capital-trusts/octopus-aim-vcts. All other statutory information will also be found there.

Financial Summary

 Six months to

31 May 2019
Six months to

31 May 2018
Year to

30 November 2018
    
Net assets (£’000s)86,84190,48090,630
(Loss)/Profit after tax (£’000s)(255)5,981(3,234)
Net asset value (‘NAV’) per share78.6p91.0p80.8p
NAV Total Return*(0.1)%6.9%(2.4)%
Dividends paid in the period2.1p2.1p4.2p
Interim dividend**2.1p2.1p2.1p

*NAV Total Return is calculated as (movements in NAV + dividends paid in the period) divided by the NAV at the beginning of the period.

**The interim dividend will be paid on 7 November 2019 to shareholders on the register on 18 October 2019.

Chairman’s Statement

I am pleased to present the half-yearly results for the Octopus AIM VCT 2 plc. The six months to 31 May 2019 has once again been a volatile period for stock market indices with early market weakness at the end of 2018 reversing and turning positive in the first half of 2019. The largest companies in the FTSE 100 have performed slightly better than smaller companies in the context of continuing uncertainty about Brexit and international trade tensions between the United States of America and China. Against this background the performance of the portfolio has been mixed and heavily influenced by individual company performance, with the Net Asset Value (NAV) ending the period almost unchanged if the dividend paid in May is added back.

Your Board has declared an interim dividend of 2.1p which will be paid in November.

Your managers have made two new investments in the six months period and these are more fully explained in their report below. The pipeline of potential new investments was weaker in the first half of the year, reflecting the fact that fewer new companies have floated, something that affected both the main market and AIM. However, despite the fact that there has to date been no resolution of the Brexit issue, existing AIM companies have continued to look for further growth capital and it is probable that there will be more new investments made in the second half of the year.

Keith Mullins

Chairman

24 July 2019

Interim Management Report

Overview

The six months to 31 May 2019 has seen the stock market make progress despite continuing headwinds from international trade tensions and Brexit uncertainty which resulted in a volatile market and individual months of negative returns. Against this less certain background larger companies marginally outperformed smaller companies, a continuation of the 2018 experience but against the long term trend.

Fundraisings on AIM were weaker, with the new issues market particularly affected in the short term. In the first five months of the year there were only nine new entrants to the AIM market although further fundraisings for existing business held up much better, demonstrating that AIM continues to support its existing members. Brexit seems to have been a distraction in the short term but we believe that the flow of opportunities will pick up again once we get through the current period of uncertainty.

Performance

Adding back the 2.1p paid out in dividends in the period, the Net Asset Value was almost unchanged in the six months to 31 May 2019. This compares with a 4.8% rise in the Smaller Companies Index (ex Investment Trusts), a 4.9% increase in the FTSE All Share Index and a 3.9% rise in AIM, all on a total return basis. Larger company Indices performed marginally better in the period reflecting an on-going cautious attitude to risk. The fund’s performance was heavily influenced by the announcement of news by individual holdings with the market very unforgiving of any disappointments. It also remained wary of early stage companies not yet making a profit, of which we hold a number in the portfolio, particularly in the pharmaceutical, medical device and technology sectors. This has proved damaging to businesses when there has been a need for further investment in situations where VCT rules do not allow the fund to follow its money. DP Poland and Haydale are two examples of this happening in the period. More recently the portfolio has benefitted from some recovery in the share prices of some of the more mature holdings after a period of underperformance towards the end of 2018 and we have taken some profits from the legacy non-qualifying holdings both before and since the half year end.

Of the good performers in the portfolio, quite a few saw their share prices react positively to corporate developments, either internally generated or as a result of acquisitions. The results season in March and April was particularly important to the more established portfolio holdings where share prices had been slow to recover from volatile conditions at the end of 2018 until they reported good figures and robust trading outlooks. Including profits taken, the biggest contributors to performance in the six months were GB Group and RWS, both of which produced strong trading statements ahead of analyst expectations in April, reflecting the benefits of earlier acquisitions. Ergomed was another strong performer with the business exceeding expectations in stark contrast to the situation a year ago when it had warned on profits. It has now focused its strategy on building a valuable and fast growing pharmaceutical services company. EKF has also continued to recover well and the initial newsflow from Renalytix which was spun out from the company has also been positive. Other mature profitable businesses to make positive contributions to performance in the period included Breedon, where trading benefitted from the Irish acquisition of Lagan and a milder winter, Gamma Communications, which delivered impressive results that led to forecast upgrades and Brooks Macdonald which is now coming towards the end of a period of concentrated investment in the business which has held back profit growth. Clinigen, Advanced Medical Solutions and Next Fifteen also reacted to good trading statements.

There were some setbacks in the portfolio which had a significant impact on performance. The largest detractor in the period was Staffline, a non-qualifying holding. After a period of very good performance in 2018, it was unable to publish its figures as expected at the end of January due to a last minute allegation over payment practices in its staffing division. This has proved slow to resolve and impacted trading while the company awaited the publication of its audited results at the end of June, accompanied by a fundraising. These events have had a considerable impact on the share price in the year to date despite the business being well established with blue chip customers. Another poor performer was Gear4 Music where the business has shown very strong growth in both Europe and the UK at the expense of margin, resulting in reduced profitability. The management is taking action to address this. Quixant shares also suffered from the news that the current year would be very second half weighted.

Portfolio Activity

In the period under review, the Company made two qualifying investments totalling £0.97 million, well behind the £4.5 million we invested in the corresponding period last year, reflecting the quieter market conditions referred to above. We invested £0.62m in Diaceutics, a company specialising in improving the availability and efficiency of diagnostic services for often hard-to-find patients who would benefit from a particular drug treatment. The Diaceutics approach is based on the analysis of large amounts of laboratory data which helps large pharmaceutical companies to launch their novel drugs more effectively. Its customers include 20 of the largest pharmaceutical companies in the world. The other investment of £0.35m was in Maxcyte, an existing holding with a proprietary technology in cell therapy which is being used in drug discovery and development and bio-manufacturing. It has also developed its own proprietary CARMA cancer treatment which has started clinical trials on humans.

In the period we also invested £502,000 of the cash balances into the FP Octopus UK Multi-Cap Income Fund, with the objective of obtaining a better return on our cash awaiting investment.

A number of disposals were made in the half year. The result has been a net gain of £0.19m, with profits being taken in RWS, Creo Medical, VR Education and Loop-up offset by the disposal of our entire holdings in Yu Group, Futura Medical and Immotion Group at a loss. Yu Group had indicated accounting irregularities and acute margin pressure on new business and in the case of Futura and Immotion we took the decision that the path to profitability would be slower and require more new investment than previously thought. We also disposed of part of the holding in Diurnal, also at a loss. Since the period end we have taken further profits from the non-qualifying portion of the portfolio after some strong share price performances.

Unquoted Investments

As stated in the investment policy the Company is able to make investments in unquoted companies intending to float. Currently 1.5% of the Company’s portfolio is invested in unquoted companies.

Transactions with Manager

Details of amounts paid to the Manager are disclosed in note 8 to the Financial Statements.

Share Buybacks

In the six months to May 2019, the Company bought back 2,217,748 Ordinary shares for a total consideration of £1,653,000. It is evident from the conversations which your Managers have that this facility remains an important consideration for investors. Your Board remains committed to maintaining its policy of buying back shares at a discount of up to 4.5% to NAV.

Share Issues

On 12 April 2019, 77,882 new shares were issued in connection with the 2018/9 prospectus offer which closed fully subscribed.

During the period 510,863 new shares were issued through the dividend reinvestment scheme (DRIS), 23,621 on 8 January 2019 and 487,242 on 24 May 2019.

Dividend

On 24 May 2019, the Company paid a dividend of 2.1p per share, being the final dividend for the year ended 30 November 2018. For the period to 31 May 2019, the Board has declared an interim dividend of 2.1p. This will be paid on 7 November 2019 to shareholders on the register on 18 October 2019.

It remains the Board’s intention to maintain a minimum annual dividend payment of 3.6p per share or a 5% yield based on the period end share price, whichever is the greater. This will usually be paid in two instalments during each year.

Risks, Uncertainties

The principal risks and uncertainties are set out in Note 7 to the half yearly report and accounts.

Outlook

The stock market has been resilient, albeit periodically volatile, despite the political failure to sort the problem of how the UK will exit the European Union in an orderly fashion. This, coupled with concerns about trading relations between the US and China continues to dominate the press, periodically causing bouts of share price volatility and weakness. For existing AIM companies it has largely been business as usual, with some notable successful fundraisings to finance acquisitions and growth, but new issues have been subdued with companies waiting before taking the decision to float.

The portfolio now contains 76 holdings across a range of sectors with the balance still weighted towards profitable companies which are continuing to pursue growth. We believe that the flow of qualifying investment opportunities should recover and we have seen several businesses considering a market debut later in the year. The VCT is currently 88.9% invested in qualifying companies with cash available for new investments.

The AIM Team
Octopus Investments
24 July 2019

Director’s Responsibilities Statement

We confirm that to the best of our knowledge:

•    the half-yearly financial statements have been prepared in accordance with Financial Reporting Standard 104 ‘Interim Financial Reporting’ issued by the Financial Reporting Council;

•    the half-yearly financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company;

•    the half-yearly report includes a fair review of the information required by the Financial Conduct Authority Disclosure and Transparency Rules, being:

•    an indication of the important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements;

•    a description of the principal risks and uncertainties for the remaining six months of the year; and

•    a description of related party transactions that have taken place in the first six months of the current financial year, that may have materially affected the financial position or performance of the Company during that period and any changes in the related party transactions described in the last annual report that could do so.

On behalf of the Board

Keith Mullins
Chairman
24 July 2019

Income Statement

 Unaudited
Six months to 31 May 2019
Unaudited
Six months to 31 May 2018
Audited
Year to 30 November 2018
 Revenue
£’000
Capital
£’000
Total
£’000
Revenue
£’000
Capital
£’000
Total
£’000
Revenue
£’000
Capital
£’000
Total
£’000
(Loss)/gain on disposal of fixed asset investments(71)(71)262262 –1,2661,266
(Loss)/gain on valuation of fixed asset investments (234)(234)6,0466,046 –(3,185)(3,185)
Gain/(loss) on valuation of current asset investments819819364364 –(155)(155)
Investment income183183234234510245755
Investment management fees(182)(547)(729)(179)(536)(715)(364)(1,093)(1,457)
Other expenses(223)(223)(210)(210)(458) –(458)
(Loss)/profit before tax(222)(33)(255)(155)6,1365,981(312)(2,922)(3,234)
Taxation on profit/(loss)  – – – – – –
(Loss)/profit after tax(222)(33)(255)(155)6,1365,981(312)(2,922)(3,234)
Return per share – basic and diluted(0.2)p0.0p(0.2)p(0.2)p6.2p6.0p(0.3)p(2.9)p(3.2)p

•    the ‘Total’ column of this statement is the profit and loss account of the Company; the supplementary revenue return and capital return columns have been prepared in accordance with the AIC Statement of Recommended Practice.

•    all revenue and capital items in the above statement derive from continuing operations.

•    the Company has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds, as well as OEIC funds.

Balance Sheet

 Unaudited
As at 31 May 2019
Unaudited
As at 31 May 2018
Audited
As at 30 November 2018
 £’000£’000£’000£’000£’000£’000
Fixed asset investments  58,510 67,387 59,871
Current assets:      
Investments20,712 17,410 16,891 
Money Market Funds3,462 4,438 3,449 
Debtors69 46 65 
Cash at bank4,542 1,779 11,546 
 28,785 23,673 31,951 
Creditors: amounts falling due within one year(454) (580) (1,192) 
Net current assets 28,331 23,093 30,759
       
Net assets 86,841 90,480 90,630
Called up equity share capital 11 10 11
Share premium 57,490 44,597 57,045
Special distributable reserve 15,557 22,621 19,536
Capital reserve realised (10,236) (10,656) (9,898)
Capital reserve unrealised 24,900 34,411 24,595
Captial redemption reserve 1 - 1
Revenue reserve (882) (503) (660)
Total equity shareholders’ funds 86,841 90,480 90,630
Net asset value per share 78.6p 91.0p 80.8p

The statements were approved by the Directors and authorised for issue on 24 July 2019 and are signed on their behalf by:

Keith Mullins
Chairman

Company Number: 05528235

Statement of Changes in Equity

 Share Capital
£’000
Share Premium
£’000
Special distributable reserves
£’000
Capital reserve realised
£’000
Capital reserve unrealised
£’000
Capital
redemption
reserve
£’000
Revenue reserve
£’000
Total
£’000
As at 1 December 20181157,04519,536(9,898)24,5951(660)90,630
Total comprehensive income for the period –  –  – (618)585 – (222)(255)
Contributions by and distributions to owners:        
Repurchase and cancellation of own shares –  –  (1,653) –  –  –  – (1,653)
Issue of shares448 –  –  –  –  – 448
Share issue costs – (3) –  –  –  –  – (3)
Dividends paid –  – (2,326)  –  –  – (2,326)
Total contributions by and distributions to owners445(3,979) – (3,534)
Prior years’ holding gains now realised280(280) –
Total other movements280(280) –
Balance as at 31 May 20191157,49015,557(10,236)24,900 1(882)86,841
         
Included in these reserves is an amount of £4,439,000 (31 May 2018: £11,462,000 and 30 November 2018: £8,978,000) which is considered distributable to shareholders.

 

.
As at 1 December 20171044,18625,444(11,071)28,690(348)86,911
Total comprehensive income for the period(274)6,410(155)5,981
Contributions by and distributions to owners:        
Repurchase and cancellation of own shares(743)(743)
Issue of shares416416
Share issue costs(5)(5)
Dividends paid(2,080)(2,080)
Total contributions by and distributions to owners411(2,823)(2,412)
Other movements:        
Prior years’ holding gains now realised689(689)
Total other movements689(689)
Balance as at 31 May 20181044,59722,621(10,656)34,411(503)90,480
         
         
As at 1 December 20171044,18625,444(11,071)28,690 – (348)86,911
Total comprehensive income for the period –  –  – 418(3,340) – (312)(3,234)
Contributions by and distributions to owners:        
Repurchase and cancellation of own shares (1) – (1,579) –  – 1 – (1,579)
Issue of shares213,662 –  –  –  – 13,664
Share issue costs – (803) –  –  –  – (803)
Dividends paid –  – (4,329) – (4,329)
Total contributions by and distributions to owners112,859(5,908)16,953
Prior years’ holding gains now realised755(755)
Total other movements755(755)
Balance as at 30 November 20181157,04519,536(9,898)24,5951(660)90,630

Cash Flow Statement

 Unaudited
Six months to
31 May 2019

£’000
Unaudited
Six months to
31 May 2018
£’000
Audited
Year to
30 November 2018
£’000
Cash flows from operating activities   
(Loss)/profit before tax(255)5,981(3,234)
Adjustments for:   
(Increase)/decrease in debtors(4)5233
(Decrease)/increase in creditors(738)7635
Loss/(gain) on disposal of fixed assets71(262)(1,266)
Loss/(gain) on valuation of fixed asset investments234(6,046)3,185
(Gain)/loss on valuation of current asset investments(819)(364)155
Non-cash distributions(245)
Cash from operations(1,511)(563)(1,337)
Income taxes paid
Net cash generated from operating activities(1,511)(563)(1,337)
    
Cash flows from investing activities   
Purchase of fixed asset investments(968)(4,494)(7,413)
Sale of fixed asset investments2,0243,0496,155
Purchase of current asset investments(3,002)(300)(300)
Net cash flows from investing activities(1,946)(1,745)(1,558)
    
Cash flows from financing activities   
Purchase of own shares(1,653)(743)(1,579)
Share issues629312,183
Dividends paid(1,943)(1,762)(3,651)
Net cash flows from financing activities(3,534)(2,412)6,953
    
(Decrease)/increase in cash and cash equivalents(6,991)(4,720)4,058
Opening cash and cash equivalents 14,99510,93710,937
    
Closing cash and cash equivalents8,0046,21714,995
Cash and cash equivalents comprise   
Cash at bank4,5421,77911,546
Money Market Funds3,4624,4383,449
 8,0046,21714,995

Notes to the Half-Yearly Report

1.  Basis of preparation

     The unaudited half-yearly report which covers the six months to 31 May 2019 has been prepared in accordance with the Financial Reporting Council’s (FRC) Financial Reporting Standard (FRS) 104 Interim Financial Reporting (March 2015) and the Statement of Recommended Practice (SORP) for Investment Companies issued by the Association of Investment Companies in 2014 (updated in February 2018).

     The Directors consider it appropriate to adopt the going concern basis of accounting. The Directors have not identified any material uncertainties to the company’s ability to continue to adopt the going concern basis over a period of at least twelve months from the date of approval of the financial statements.

     The principal accounting policies have remained unchanged from those set out in the Company’s 2018 Annual Report and Accounts.

2.  Publication of non-statutory accounts

     The unaudited half-yearly reports for the six months ended 31 May 2019 does not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006. The comparative figures for the year ended 30 November 2018 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor’s report on those financial statements, in accordance with chapter 3, part 16 of the Companies Act 2006, was unqualified. This half-yearly report has not been reviewed by the Company’s auditor.

3.  Earnings per share

     The earnings per share at 31 May 2019 are calculated on the basis of 111,279,985 shares (31 May 2018: 99,400,679 and 30 November 2018: 101,274,833), being the weighted average number of shares in issue during the period.

     There are no potentially dilutive capital instruments in issue and, therefore, no diluted returns per share figures are relevant.

4.  Net asset value per share

     The net asset value per share is based on net assets as at 31 May 2019 divided by 110,500,001 shares in issue at that date (31 May 2018: 99,391,431 and 30 November 2018: 112,129,004).

5.  Dividends

     The Directors have declared a dividend of 2.1 pence per share, payable from the special distributable reserve. This dividend will be paid on 7 November 2019 to those shareholders on the register at 18 October 2019.

6. Buybacks and share issues

     During the six months ended 31 May 2019 the Company repurchased the following shares.

DateNo. of sharesPrice (p)Cost (£)
13 December 2018324,32074.6242,000
24 January 2019259,12774.7194,000
14 February 2019350,00073.1256,000
21 March 2019369,37173.9273,000
18 April 2019195,43074.9146,000
23 May 2019719,50075.4542,000
Total2,217,748 1,653,000

     The weighted average price of all buybacks during the period was 74.5 pence per share.

     During the six months ended 31 May 2019 the Company issued the following shares:

DateNo. of sharesPrice (p)Net proceeds (£)
8 January 2019 (DRIS)*23,621--
12 April 2019 77,88282.562,000
24 May 2019 (DRIS)487,24278.8383,000
Total588,745 445,000

The weighted average allotment price of all shares issued during the period was 75.6 pence per share.

*Issued in correction of a previous pricing error.

7. Principal risks and uncertainties

     The Company’s principal risks are VCT qualifying status risk, investment risk, valuation risk, regulatory and reputational risk, operational risk and financial risk; market price risk, credit risk, liquidity risk, fair value risk, cash flow risk and interest rate risk. These risks, and the way in which they are managed, are described in more detail in the Company’s Annual Report and Accounts for the year ended 30 November 2018. The Company’s principal risks and uncertainties have not changed materially since the date of that report.

8. Related party transactions

     The Company has employed Octopus Investments Limited (“Octopus” or “the Manager”) throughout the period as Investment Manager. Octopus has also been appointed as Custodian of the Company’s investments under a Custodian Agreement. The Company has been charged £729,000 by Octopus as a management fee in the period to 31 May 2019 (31 May 2018: £715,000 and 30 November 2018: £1,457,000). The management fee is payable quarterly and is based on 2% of net assets at quarterly intervals.

     The Company receives a reduction in the management fee for the investments in other Octopus managed funds, being the Octopus Portfolio Manager and Micro Cap products, to ensure the Company is not double charged on these products. This amounted to £35,000 in the period to 31 May 2019 (31 May 2018: £31,000 and 30 November 2018: £63,000). For further details please refer to the Company’s Annual Report and Accounts for the year ended 30 November 2018.

9. Post balance sheet events

     The following events occurred between the balance sheet date and the signing of these financial statements:

•    20 June 2019: 161,371 shares bought back at a price 74.4p per share.

•    28 June 2019: 38,671 shares issued at a price of 77.3p.

•    Partial disposals in RWS Holdings plc, Clinigen Group plc, Gamma Communications plc, Next Fifteen Communications plc, Restore plc, Advanced Medical Solutions Group plc and Iomart Group plc. Total consideration for the seven holdings was £1.6 million.

•    Full disposal of holding in Abcam plc for total consideration of £574,000.

•    One follow-on investment into the UK Multi Cap Income Fund of £50,000.

•    The Company has cancelled £11.6 million of share premium.

10. Fixed asset investments

     Accounting Policy

     The Company’s principal financial assets are its investments and the policies in relation to those assets are set out below.

     Purchases and sales of investments are recognised in the financial statements at the date of the transaction (trade date).

     These investments will be managed and their performance evaluated on a fair value basis in accordance with a documented investment strategy and information about them has to be provided internally on that basis to the Board. Accordingly, as permitted by FRS 102, the investments are measured as being fair value through profit or loss on the basis that they qualify as a group of assets managed, and whose performance is evaluated, on a fair value basis in accordance with a documented investment strategy. The Company’s investments are measured at subsequent reporting dates at fair value.

     In the case of investments quoted on a recognised stock exchange, fair value is established by reference to the closing bid price on the relevant date or the last traded price, depending upon convention of the exchange on which the investment is quoted. This is consistent with the International Private Equity and Venture Capital Valuation (IPEV) guidelines.

     Gains and losses arising from changes in fair value of investments are recognised as part of the capital return within the Income Statement and allocated to the Capital reserve – unrealised. The Managers review changes in fair value of investments for any permanent reductions in value and will give consideration to whether these losses should be transferred to the Capital reserve – realised.

     In the preparation of the valuations of assets the Directors are required to make judgements and estimates that are reasonable and incorporate their knowledge of the performance of the investee companies.

     Fair value hierarchy

     Paragraph 34.22 of FRS102 suggests following a hierarchy of fair value measurements, for financial instruments measured at fair value in the Balance Sheet, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). This methodology is adopted by the Company and requires disclosure of financial instruments to be dependent on the lowest significant applicable input, as laid out below:

     Level 1: The unadjusted, fully accessible and current quoted price in an active market for identical assets or liabilities that an entity can access at the measurement date.

     Level 2: Inputs for similar assets or liabilities other than the quoted prices included in Level 1 that are directly or indirectly observable, which exist for the duration of the period of investment.

     Level 3: This is where inputs are unobservable, where no active market is available and recent transactions for identical instruments do not provide a good estimate of fair value for the asset or liability.

     There have been no reclassifications between levels in the year. The change in fair value for the current and previous year is recognised through the profit and loss account.

     Disclosure

  Level 1:
AIM-traded equity investments
£’000
Level 3:
Unquoted investments
£’000
Total
£’000
Cost as at 1 December 201834,5801,38735,967
Opening unrealised gain/(loss) at 1 December 201823,66324123,904
Valuation at 1 December 201858,2431,62859,871
    
Purchases at cost968-968
Disposal proceeds(2,024)-(2,024)
Profit on realisation of investments (71)(71)
Change in fair value in year(234)-(234)
Closing valuation at 31 May 201956,8821,62858,510
    
Cost at 31 May 201934,0781,05735,135
Closing unrealised gain at 31 May 201923,13424123,375
Valuation at 31 May 201957,2121,29858,510

      Level 1 valuations are valued in accordance with the bid-price on the relevant date. Further details of the fixed asset investments held by the Company are shown within the Investment Manager’s Review.

     Level 3 investments are valued in accordance with IPEV guidelines. Hasgrove is valued at the most recent transaction price, whilst Rated People is valued at the latest fundraise price. Fusionex is held at the latest traded price as a listed company before delisting. The one loan note is held at cost which is deemed to be current fair value.

     All capital gains or losses on investments are classified at FVTPL. Given the nature of the Company’s venture capital investments, the changes in fair value of such investments recognised in these financial statements are not considered to be readily convertible to cash in full at the balance sheet date and accordingly these gains are treated as holding gains or losses.

     At 31 May 2019 there were no commitments in respect of investments approved by the Investment Manager but not yet completed.

11. Additional information

     Copies of this report are available from the registered office of the Company at 33 Holborn, London, EC1N 2HT.


Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Half-year report - RNS